Navigation Links
JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
Date:8/6/2013

are not historical facts.  These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with maintaining and increasing sales of and revenue from Xyrem, such as the potential introduction of generic competition and changed or increased regulatory restrictions on or requirements with respect to Xyrem, as well as similar risks related to effectively commercializing the company's other marketed products, including Erwinaze and Prialt; protecting and expanding the company's intellectual property rights; obtaining appropriate pricing and reimbursement for the company's products in an increasingly challenging environment; ongoing regulation and oversight by U.S. and non-U.S. regulatory agencies; dependence on key customers and sole source suppliers, including the risk that the company may not be able to timely resolve potential product supply shortages and meet product demand; the difficulty and uncertainty of pharmaceutical product development and the uncertainty of clinical success and regulatory approval; the company's ability to identify and acquire, in-license or develop additional products or product candidates to grow its business; and possible restrictions on the company's ability and flexibility to pursue certain future opportunities as a result of its substantial outstanding debt obligations; as well as risks related to future opportunities and plans, including the uncertainty of expected future financial performance and results; and those other risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No
'/>"/>
SOURCE Jazz Pharmaceuticals plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
2. Inovio Pharmaceuticals Responds to Market Activity
3. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
4. Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Bausch + Lomb
5. Avanir Pharmaceuticals to Participate in Two Conferences in August
6. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
7. AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
8. Isis Pharmaceuticals Reports Data From a Phase 2 Study of Isis-CRP Rx in Patients with Rheumatoid Arthritis
9. Intercept Pharmaceuticals to Present at the Wedbush Securities Life Sciences Management Access Conference
10. GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
11. GW Pharmaceuticals plc Reports 2013 Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx") today ... from the Israeli patent office with claims for administering ... damage caused by an increase in blood flow, as ... after a blockage causing a heart attack or in ... can be caused to the heart attack or stroke ...
(Date:3/26/2015)... March 26, 2015  Flexpoint Sensor Systems, Inc. (OTCBB: ... it has received and shipped during the last 90 ... of interest in the sensors for gloves and medical ... have had custom sensors built for them. Some of ... custom sensors for medical rehab; a major international electronics ...
(Date:3/26/2015)... VEGAS , March 26, 2015 ... sales agreement with Radlink, Inc., an emerging global ... real-time image guidance with its hip replacement systems. ... commitment to help improve patient outcomes, increase patient ... conjunction with the 81st annual meeting of the ...
Breaking Medicine Technology:RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3Flexpoint Sensor Systems, Inc. Expands Customer Base with New Orders of Sensors 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 2DePuy Synthes Companies Announces Exclusive Agreement With Radlink To Help Address Key Challenges In Hip Replacement 3
... Mylan Inc. (Nasdaq: MYL ) today ... entered into a settlement agreement with Warner Chilcott resolving ... as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 ... mg (28-Day Regimen). This medication is an oral contraceptive. ...
... NEW YORK, Oct. 19, 2011 Reportlinker.com announces ... in its catalogue: Syncria ... 2020 http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Forecasts to 2020 Summary ...
Cached Medicine Technology:Mylan Announces Femcon® Fe Settlement Agreement 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
(Date:3/26/2015)... On March 5, 2015, Portland Trail Blazers ... the season with a torn Achilles tendon in his ... were competing against Dallas, and was confirmed via an ... M.D., who has treated many professional athletes, voiced his ... be prevented. , "Part of the problem regarding ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The ... the Patients’ Access to Treatments Act (PATA) that ... week by Reps. David B. McKinley (R-WV) and ... limit cost-sharing requirements for medications placed in a ... by reducing patients’ out-of-pocket expenses. , This legislation ...
(Date:3/26/2015)... 26, 2015 Volunteers will collectively walk ... Parkinson’s disease and funds to support the American ... Burden – Find the Cure. The Optimism ... place in more than 20 locations including, Boston, Chicago, ... San Antonio, Minnesota, Seattle, St. Louis, New York, Nevada, ...
(Date:3/26/2015)... 26, 2015 In preparation for the ... Revolution, founded by Samir Becic, has issued “report ... personal health and fitness, as well as their promotion ... list includes Sen. Ted Cruz, who has officially announced ... all other politicians who have shown interest in running ...
(Date:3/26/2015)... CRN International took the podium this ... celebrate the achievement of jobseekers from five statewide locations ... 500 people. , The program, called Platform to Employment ... partnership with the Connecticut Department of Labor, takes active ... and place them at appropriate companies. CRN, a 40-year-old ...
Breaking Medicine News(10 mins):Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4Health News:Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act 2Health News:American Parkinson Disease Association 2015 Optimism Walk Season Launches Nationwide 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 2Health News:How the Candidates for the 2016 Presidential Election Rank in Health and Fitness 3Health News:CRN International Shows Support For Groundbreaking Connecticut Program To Aid The Unemployed 2
... can be significantly reduced by providing a simple intervention ... and alternatives of various imaging modalities, according to a ... Island, NY. , "Given the increased awareness ... medical imaging we hypothesized that a simple intervention of ...
... a strong relationship with their parents may start drinking at ... risk of developing alcohol problems, a new study suggests. , ... Journal of Studies on Alcohol and Drugs , underscore the ... , Past studies have suggested that the age at which ...
... A new study shows that the SAVI applicator, a ... partial breast irradiation, carries a low infection risk, a ... radiation oncologists and surgeons at the Moores UCSD Cancer ... indicates that other complications such as seromas, pockets ...
... (NYSE: VRX ) today announced that results ... clinical trial for taribavirin, a prodrug of ribavirin which ... C in conjunction with a pegylated interferon, was presented ... Liver (EASL) 44th Annual Meeting in Copenhagen, Denmark. ...
... at higher risk of aggressive recurrence only 8 months ... U.S. male military veterans exposed to the Agent Orange ... prostate cancer, a new study finds. , It included ... Of those, the 206 men who,d been exposed to ...
... NBTY, Inc. (NYSE: NTY ) ( www.NBTY.com ... supplements, today announced results for the fiscal second quarter and ... quarter ended March 31, 2009, net sales were $596 million ... March 31, 2008, an increase of $63 million or 12%. ...
Cached Medicine News:Health News:Good relationship with parents may prevent teen drinking problems 2Health News:Radiation device in the breast reduces complications for early stage breast cancer patients 2Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 2Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 3Health News:Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting 4Health News:Agent Orange Exposure Tied to Prostate Cancer Return 2Health News:NBTY Reports Second Quarter Results 2Health News:NBTY Reports Second Quarter Results 3Health News:NBTY Reports Second Quarter Results 4Health News:NBTY Reports Second Quarter Results 5Health News:NBTY Reports Second Quarter Results 6Health News:NBTY Reports Second Quarter Results 7Health News:NBTY Reports Second Quarter Results 8Health News:NBTY Reports Second Quarter Results 9Health News:NBTY Reports Second Quarter Results 10Health News:NBTY Reports Second Quarter Results 11Health News:NBTY Reports Second Quarter Results 12Health News:NBTY Reports Second Quarter Results 13Health News:NBTY Reports Second Quarter Results 14Health News:NBTY Reports Second Quarter Results 15Health News:NBTY Reports Second Quarter Results 16Health News:NBTY Reports Second Quarter Results 17Health News:NBTY Reports Second Quarter Results 18Health News:NBTY Reports Second Quarter Results 19Health News:NBTY Reports Second Quarter Results 20
This is an Immunological assay intended for the quantitative in vitro determination of haemoglobin A1c (HbA1c) in whole blood....
For the quantitative in vitro determination of Sodium in serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: